BID, BH3 interacting domain death agonist, 637

N. diseases: 117; N. variants: 5
Disease: Leukemia, Myeloid, Chronic-Phase ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023474
Disease: Leukemia, Myeloid, Chronic-Phase
Leukemia, Myeloid, Chronic-Phase 		0.010 Biomarker disease BEFREE Nilotinib (300/400 mg BID), dasatinib (100 mg QD) and radotinib (300 mg BID) prove to be the most recommended front-line treatments of the greatest efficacy and tolerability for CP-CML patients. 31462241 2019